BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH. Celares provides customized bioconjugation solutions
BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH. Celares provides customized bioconjugation solutions
Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics
BroadOak Capital Partners invested in Indee Labs out of its BioTools Venture Fund to support the
Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine
BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing
BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million
BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services,
BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization)
BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a
It is an exciting time at BroadOak as we help advance innovative life sciences technologies.
Holly Atallah
Director of Finance & Operations
BroadOak has advised and invested in life sciences companies for over 15 years. Get to know us.